MLC1501

DRUG3 trials

Sponsors

Moleac Pte Ltd.

Conditions

StrokeStroke SequelaeStroke, CardiovascularStroke, CryptogenicStroke, EmbolicStroke, IschemicStrokes Thrombotic

Phase 1

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

CompletedNCT04233437

Moleac Pte Ltd.Stroke

Start: 2020-02-10End: 2020-05-16Updated: 2020-09-03

Phase 2

MLC1501 Study Assessing Efficacy in STROke Recovery

Not yet recruitingNCT05046106

Moleac Pte Ltd.Stroke, Stroke, Cardiovascular, Stroke, Cryptogenic +4

Start: 2025-01-31End: 2028-12-31Target: 540Updated: 2023-03-16

MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

CompletedNCT05289947

Moleac Pte Ltd.Stroke, Stroke, Cardiovascular, Stroke, Cryptogenic +4

Start: 2023-07-21End: 2025-07-18Updated: 2025-12-09

Related Papers

Phase II randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of MLC1501 in patients with stroke: the MLC1501 study Assessing Efficacy in post-STrOke Subjects with mOtor deficits (MAESTOSO) study protocol.

2025-10-27